Prostate cancer (PCa) is the second most common cancer diagnosed in men world-wide.1 Cellular signalling events derived from activation of the androgen receptor (AR) pathway play a prominent role in PCa development and progression.2,3 Consequently, first-line treatment options for PCa patients have focused on androgen deprivation therapy (ADT) which includes androgen ablation and AR inhibition.3–6 Despite the many advances in chemotherapy, most PCa tumours develop resistance over time. Here, AR is linked to prostate carcinoma.